Ovid Therapeutics Inc is a biopharmaceutical company dedicated to discovering and developing small molecule medicines that address brain disorders with significant unmet medical need. The company concentrates on the central nervous system where it aims to reduce neuronal hyperexcitability by modulating key enzymes and ion channels such as GABA aminotransferase and the potassium chloride cotransporter KCC2. By restoring inhibitory tone Ovid Therapeutics hopes to alter disease progression and relieve symptoms including seizures psychosis and related neuropsychiatric manifestations. The firm vision is to build a fully integrated neurotherapeutics enterprise with multiple clinical stage programs and eventual commercial medicines that deliver first in class or best in class therapeutic profiles. Over the last decade Ovid Therapeutics has advanced a pipeline that includes a next generation GABA aminotransferase inhibitor OV329 and a portfolio of direct activators of KCC2 such as OV4071. These programs are designed to offer improved efficacy safety and tolerability compared with existing therapies.

Ovid Therapeutics generates revenue chiefly from license agreements collaborations milestone payments and royalties received from partners. In December 2021 the company entered into an exclusive worldwide license with AstraZeneca for a portfolio of more than 100 small molecule compounds that activate the KCC2 transporter receiving an upfront cash payment of five million dollars and equity valued at seven point three million dollars. Under this agreement Ovid Therapeutics may earn clinical development milestones up to eight million dollars regulatory milestones up to forty five million dollars and total commercial milestones up to one hundred fifty million dollars plus tiered royalties ranging from single digits to ten percent on net sales. In March 2022 Ovid Therapeutics out licensed its ganaxolone related patents to Marinus Pharmaceuticals granting Marinus exclusive rights in the United States Europe the United Kingdom and Switzerland for CDKL5 deficiency disorder. The agreement included an option for Marinus to receive shares upon FDA approval and provided for single digit royalties on net sales. In January 2025 Marinus was acquired by Immedica Pharma and in June 2025 Ovid Therapeutics received a seven million dollar cash payment to replace ongoing royalty obligations and to add additional patents to the licensed portfolio. The company also holds a license from Northwestern University for OV329 requiring an upfront fee of seventy five thousand dollars and an annual maintenance fee of twenty thousand dollars creditable against future royalties plus potential milestone payments up to five point three million dollars and low to mid single digit royalties on net sales. Additionally Ovid Therapeutics has a license agreement with H Lundbeck A S for OV101 gaboxadol which was later discontinued in early 2021. The firm also entered into a research collaboration and equity investment with Gensaic Inc in 2022 investing five point one million dollars for convertible preferred stock and agreeing to develop up to three genetic medicines for neurological indications using Gensaic tissue selective intracellular delivery platform. Revenues may also arise from future product sales once any of its pipeline candidates obtains regulatory approval and reaches the market.

Ovid Therapeutics competes in the neurology and psychiatry treatment landscapes where the epilepsy market is estimated at approximately eight billion dollars globally and the antipsychotic market at around twenty two billion dollars globally. The company sees substantial growth prospects driven by the high unmet need in these therapeutic areas and by recent industry consolidation where epilepsy and psychiatric medicines companies have been acquired for values ranging from two point six billion to fourteen point six billion dollars. Direct competitors for Ovid Therapeutics GABA aminotransferase inhibitor OV329 include UCB Jazz Pharmaceuticals SK Biopharmaceuticals Harmony Biosciences and Xenon Pharmaceuticals which market anti seizure agents for similar indications such as drug resistant focal onset seizures and developmental epileptic encephalopathies. For its KCC2 direct activator programs targeting psychosis associated with Parkinson disease and Lewy body dementia the primary approved therapy is Nuplazid marketed by Acadia Pharmaceuticals. Ovid Therapeutics also notes potential competition from Axonis Therapeutics which is investigating KCC2 potentiators. The firm competitive advantages arise from its differentiated mechanisms of action its first in class portfolio of KCC2 direct activators and its strong intellectual property position. Ovid Therapeutics holds composition of matter patents covering OV329 that extend to 2036 and a pending global patent application for the KCC2 activator library that if issued would provide protection until 2041. The company further benefits from its scientific approach that utilizes biomarker strategies clinically translatable preclinical models and meaningful endpoints to de risk development and increase the probability of success. Its management team brings extensive experience in developing and commercializing central nervous system medicines having contributed to the launch of products such as Zolgensma Ztalmy Fintepla Brineura Gilenya Tysabri and Tecfidera.

Ovid Therapeutics serves patients who suffer from epilepsy developmental and epileptic encephalopathies psychosis associated with Parkinson disease and Lewy body dementia schizophrenia and related mood disorders. Epidemiology data show that roughly fifty million people worldwide live with epilepsy including about three million adults and five hundred thousand children in the United States. A significant proportion of epilepsy patients experience drug resistant seizures with rates ranging from fifty percent to ninety percent in rare epileptic encephalopathies. The company also addresses psychosis in neurodegenerative conditions where today more than four point three million individuals globally live with psychosis linked to Parkinson disease or Lewy body dementia of which approximately 1 point five million are in the United States for Lewy body dementia and another one million experience psychosis associated with Parkinson disease. In addition to patients Ovid Therapeutics works with healthcare providers hospitals neurology and psychiatry clinics and specialty care centers that diagnose and treat these conditions. The firm collaborates with pharmaceutical partners academic institutions and research organizations to advance its drug candidates and to gain access to patient populations for clinical trials. While the company has not yet commercialized a product its future customer base will include patients caregivers physicians pharmacies and payers who seek effective safe and well tolerated therapies for neurological and psychiatric illnesses.